Quintiles Transitional Holdings (Q) Shares are Up 2.08%

Quintiles Transitional Holdings (Q) : Traders are bullish on Quintiles Transitional Holdings (Q) as it has outperformed the S&P 500 by a wide margin of 5.9% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.91%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.08% in the last 1 week, and is up 5.33% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 3.95% and the 50-Day Moving Average is 5.34%.The 200 Day SMA reached 17.93%


Quintiles Transitional Holdings (NYSE:Q): After opening at $79.18, the stock dipped to an intraday low of $79.01 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $81.255 and the buying power remained strong till the end. The stock closed at $81.06 for the day, a gain of 2.53% for the day session. The total traded volume was 2,438,185. The stocks close on the previous trading day was $81.06.

Quintiles Transitional Holdings (Q) : Average target price received by Quintiles Transitional Holdings (Q) is $81.4 with an expected standard deviation of $4.79. The most aggressive target on the stock is $88, whereas the most downbeat target is $73. 10 financial analysts are currently covering the stock.

Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *